Different CAR immune cells have different advantages and unique challenges or limitations. However, the expansion of CARs to other cell types has already begun and shows promising results. Here, we discuss alternative CAR-cell types such as CAR Natural Killer (CAR-NK) cells due to their current standing as the most popular alternative CAR-based therapy along with CAR macrophages (CAR-MF).

Chimeric antigen receptor T-cells (CAR-T) are one of the first clinically approved therapies to take advantage of the most significant advancements in immunology and genetic engineering. We explore the top new cell contenders in the growing CAR-T field including chimeric antigen receptor natural killer cells (CAR-NK) and the several characteristics which make them appealing for cancer therapy.

Roughly 50 million people in the U.S. are afflicted with an autoimmune disease, costing more than $100 billion dollars in annual healthcare costs. Unlike conditions such as cancer, there is no cure for autoimmune disease and treatment options are very limited. Take a closer look at the power of CAR-T and its clinical relevance beyond cancer therapy as a powerful method to combat autoimmunity.